Two Sigma Advisers
CAPR icon

Two Sigma Advisers’s Capricor Therapeutics CAPR Stock Holding History

Two Sigma Advisers’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-74,200
Closed -$535K – 2372
2025
Q3 		$535K Buy
74,200
+13,578
+22% +$100K ﹤0.01% 1733
2025
Q2 		$602K Buy
+60,622
New +$640K ﹤0.01% 1668
2020
Q3 		– Sell
-21,130
Closed -$97K – 2417
2020
Q2 		$97K Buy
+21,130
New +$92.1K ﹤0.01% 2363

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's CAPR Position: Q4 2025 in Review

Two Sigma Advisers sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 74,200 shares — an estimated $535K sold.

Two Sigma Advisers first reported a position in CAPR in Q2 2020 and held it in 3 quarters. The position peaked at $602K in Q2 2025. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • Two Sigma Advisers reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 74,200 Capricor Therapeutics shares in Q4 2025, an estimated $535K.
  • Two Sigma Advisers first reported a position in Capricor Therapeutics in Q2 2020 and held it in 3 quarters.
  • Two Sigma Advisers's Capricor Therapeutics position peaked at $602K in Q2 2025.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.